Phaseline

Companies › Bolt Biotherapeutics

Bolt Biotherapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout May 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
BDC-4182
Anti-CLDN18.2 monoclonal antibody conjugated to TLR7/8 dual agonist
CLDN18, TLR7, TLR8Phase 1Gastric Cancer Adenocarcinoma MetastaticMay 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06921837BDC-4182Phase 1Gastric Cancer Adenocarcinoma MetastaticOncologyMay 2027

From the company's SEC filings

Cash and short-term investments of $18m on 2026-06-30; operating cash outflow about $30m a year; runway about 7 months at that burn, to Feb 2027

Press releases filed as 8-K in the last year:

Agreements filed with the SEC (item 1.01), last two years

Specialist investors

Held by 2 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

CLDN18 (1) TLR7 (1) TLR8 (1)

Companies with the same targets

Merck KGaA Astellas AstraZeneca Eikon Therapeutics United Immunity Beeline Medicines HighField Biopharmaceuticals Ascendis Pharma Oncology Division Inimmune RemeGen

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.